ArticleMaterials today. Bio2025
Bioinformatics driven in gene targeting platform for gold anticancer strategy delivery.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Owing to its high degree of malignancy and poor survival outcomes, triple-negative breast cancer (TNBC) is considered the most invasive subtype of breast cancer. In the realm of TNBC treatment, clinical practice continues to be predominantly characterized by the utilization of chemotherapy regimens. The development of anticancer therapies that are specifically targeted and precise in their action remains a significant challenge within this therapeutic domain. This study aims to discover new target genes and develop nucleic acid delivery systems. In this study, we identified the differentially expressed gene SDC1, which exhibited high levels of expression in TNBC and correlates with poorer overall survival trends through a comprehensive gene chip data screening analysis. The results of our analysis suggest a positive correlation between increased SDC1 expression levels and etoposide drug resistance in cases of TNBC. For mechanistic insights, scRNA-seq was employed to map SDC1-dependent alterations in the tumor microenvironment (TME) immune architecture. In view of this, the present study successfully constructed an
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.